Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

12/09/25

Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

...

Poolbeg granted FDA Orphan Drug Designation for POLB 001

05/27/25

Poolbeg granted FDA Orphan Drug Designation for POLB 001

...

Cytokine release syndrome preventative therapy could be a >$10bn market opportunity

02/12/24

Cytokine release syndrome preventative therapy could be a >$10bn market opportunity

...

Positive outputs from lab-based analysis of RSV drug candidates identified using AI

12/20/23

Positive outputs from lab-based analysis of RSV drug candidates identified using AI

...

Poolbeg Pharma PLC announces directorate change

12/01/23

Poolbeg Pharma PLC announces directorate change

...

Poolbeg Pharma to use unique oral delivery platform for new condition

10/17/23

Poolbeg Pharma to use unique oral delivery platform for new condition

...

Poolbeg Pharma completes clinical trials for viral strain agnostic

12/12/22

Poolbeg Pharma completes clinical trials for viral strain agnostic

...

Poolbeg-led consortium awarded €2.3m in funding

11/16/22

Poolbeg-led consortium awarded €2.3m in funding

...

Poolbeg Pharma
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.